评估至治疗间隔与转移灶活检部位对黑色素瘤PD-L1表达1%阈值预测价值的影响
这项全国性队列研究利用丹麦转移性黑色素瘤数据库和丹麦病理登记库,分析2017年1月至2024年2月接受抗PD-1或抗PD-1联合抗CTLA-4治疗的1137例转移性黑色素瘤患者。结果显示,在治疗前90天内评估PD-L1时,1%阈值可预测结局;非淋巴结转移灶似乎更可取。
要点
- 治疗前90天内评估PD-L1时,1%阈值对转移性黑色素瘤具有预测价值。
- PD-L1<1%患者中,联合治疗较单药改善PFS和OS;PD-L1≥1%患者中两者结局相当。
- 非淋巴结转移灶(皮肤/皮下、内脏)的PD-L1评估似乎更可取。
核心结论
- 当使用ICI启动前90天内获取的组织进行评估时,PD-L1似乎是转移性黑色素瘤可靠的预测性生物标志物。
- 非淋巴结转移部位似乎更可取。
研究设计与样本
- 全国性队列研究,使用丹麦转移性黑色素瘤数据库(DAMMED)和丹麦病理登记库。
- 分析2017年1月至2024年2月接受抗PD-1或抗PD-1联合抗CTLA-4治疗的转移性黑色素瘤患者,共1137例。
- 采用Log-rank检验和Cox回归分析无进展生存期(PFS)和总生存期(OS)。
主要发现
- 在治疗前90天内评估PD-L1的患者(n=964;55.2% PD-L1<1%,44.8% PD-L1≥1%)中,PD-L1<1%患者联合治疗改善结局(PFS aHR 0.62;95%CI 0.48-0.80;p<0.001;OS aHR 0.64;95%CI 0.48-0.85;p=0.002)。
- PD-L1≥1%患者中联合治疗与单药结局相当(PFS aHR 0.90;95%CI 0.62-1.30;p=0.57;OS aHR 0.97;95%CI 0.60-1.57;p=0.89)。
- PD-L1评估距治疗>90天者(n=173)中,上述模式较不明显。
- 48对同一器官的配对PD-L1评估中,不一致率为25%。
- PD-L1<1%皮肤/皮下转移患者联合治疗改善PFS(aHR 0.51;95%CI 0.34-0.76;p<0.001),内脏转移患者(aHR 0.65;95%CI 0.42-1.02;p=0.060)未达统计学显著,淋巴结转移患者未见此关联(aHR 0.79;95%CI 0.48-1.29;p=0.35)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intratumoral PD-L1 expression at the 1 % cut-off predicts clinical outcomes and may guide first-line immune checkpoint inhibitor (ICI) selection for metastatic melanoma (MM). However, the impact of the interval between PD-L1 assessment and ICI initiation and the metastatic site used for PD-L1 evaluation, remains unclear. METHODS: In this nationwide cohort study we used the Danish Metastatic Melanoma Database (DAMMED) and the Danish Pathology Registry to analyze patients with MM treated with anti-PD-1 or anti-PD-1 plus anti-CTLA-4 from January 2017 to February 2024. Progression-free survival (PFS) and overall survival (OS) were analyzed using Log-rank tests and Cox regression. RESULTS: Data from 1137 patients were analyzed. Among patients with PD-L1 assessed within 90 days of treatment (n = 964; 55.2 % PD-L1 <1 %, 44.8 % PD-L1 ≥1 %), combination therapy improved outcomes in PD-L1 < 1 % (PFS adjusted (a)HR 0.62; 95 % CI 0.48-0.80; p < 0.001, OS aHR 0.64; 95 % CI 0.48-0.85; p = 0.002), while outcomes were comparable for PD-L1 ≥ 1 % patients (PFS aHR 0.90; 95 % CI 0.62-1.30; p = 0.57, OS aHR 0.97; 95 % CI 0.60-1.57; p = 0.89). For PD-L1 assessed > 90 days prior (n = 173), this pattern was less pronounced. Among 48 paired PD-L1 assessments from the same organ, discordance occurred in 25 %. Combination therapy improved PFS for patients with PD-L1 < 1 % skin/subcutaneous (aHR 0.51; 95 % CI 0.34-0.76; p < 0.001) and visceral metastases (aHR 0.65; 95 % CI 0.42-1.02; p = 0.060) while this association was not evident for lymph node metastases (aHR 0.79; 95 % CI 0.48-1.29; p = 0.35). CONCLUSIONS: PD-L1 seems a reliable predictive biomarker in MM, when assessed on tissue obtained within 90 days prior to ICI initiation. Non-nodal metastatic sites appear preferable.
引用
- Vestergaard CD, Donia M, Madsen K, et al. Impact of assessment-to-treatment interval and metastatic biopsy site on the predictive value of PD-L1 expression at the 1 % cut-off level in melanoma. Eur J Cancer. 2025. PMID: 40222200. doi:10.1016/j.ejca.2025.115402
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。